Doctor of Osteopathy Program year 2024 Reported 2019–2024 Source: CMS Open Payments, 2026 publication

Kevin McGeehan

Neurology Warsaw, IN Doctor of Osteopathy

NPI 1871581561 CMS profile 85355

3505 Lake City Hwy, Warsaw, IN 46580

Open in the dashboard

General payments

$1,954

160 records reported · program years 2019–2024

Research payments

$0

Paid to them · None reported · program years 2019–2024

Ownership & investment interest

$0

None reported

Through program year 2024, Kevin McGeehan of Warsaw, IN is reported in the CMS Open Payments database as having received $1,954 across 160 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 54th percentile of Neurology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

4 rows
Year Kind Relative to this record's peak year Amount Records
2024 General $15 1
2021 General $25 2
2020 General $344 25
2019 General $1,569 132

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Kevin McGeehan
  • Neurology median
  • Middle half of Neurology
  • National median

In program year 2025, general payments to Kevin McGeehan were reported at $0. Among 11,022 Neurology profiles paid that year, the median was $457 and the middle half received between $118 and $2,344.

Show as a table
Year Kevin McGeehan Neurology median Middle half National median
2019 $1,569 $474 $118–$2,177 $163
2020 $344 $367 $82–$2,309 $114
2021 $25 $438 $104–$2,547 $132
2022 $0 $442 $103–$2,388 $149
2023 $0 $464 $119–$2,312 $160
2024 $15 $468 $119–$2,323 $164
2025 $0 $457 $118–$2,344 $169

Breakdown

Who paid General payments · program years 2019–2024
  1. Supernus Pharmaceuticals, Inc. $412 35 payments
  2. UCB, Inc. $338 31 payments
  3. Sunovion Pharmaceuticals Inc. $188 21 payments
  4. Genzyme Corporation $151 10 payments
  5. Teva Pharmaceuticals USA, Inc. $125 11 payments
  6. Lilly USA, LLC $99 7 payments
  7. Adamas Pharmaceuticals, Inc. $99 7 payments
  8. Amgen Inc. $90 6 payments
  9. Neurocrine Biosciences, Inc. $84 5 payments
  10. ACADIA Pharmaceuticals Inc $66 5 payments
  11. Other $302 22 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2024
  1. Food and Beverage $1,954 160 payments
Products named General payments · program years 2019–2024
  1. TROKENDI XR $412 35 payments
  2. APTIOM $188 21 payments
  3. Vimpat $167 17 payments
  4. Ajovy $125 11 payments
  5. AUBAGIO $119 8 payments
  6. EMGALITY $99 7 payments
  7. GOCOVRI $99 7 payments
  8. Neupro $96 7 payments
  9. AIMOVIG $90 6 payments
  10. INGREZZA $84 5 payments
  11. Other $545 40 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 74 drugs

Part D claims

5,780

Median for Neurology: 833

Drug cost

$1,497,184

Median for Neurology: $202,670

Branded share of claims

26.2%

Median for Neurology: 25.9%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Aubagio Teriflunomide Brand 33 $375,578
Ingrezza Valbenazine Tosylate Brand 31 $253,963
Gammaplex Immun Glob G(Igg)/Gly/Iga 0-50 Brand 11 $92,200
Teriflunomide Generic 47 $79,796
Ubrelvy Ubrogepant Brand 68 $70,885
Copaxone Glatiramer Acetate Brand 12 $65,081
Qulipta Atogepant Brand 34 $64,671
Emgality Pen Galcanezumab-Gnlm Brand 79 $62,237
Neupro Rotigotine Brand 44 $51,784
Namzaric Memantine Hcl/Donepezil Hcl Brand 60 $45,568

The 10 drugs with the highest cost, of 74 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 13,695 Part D prescribers listed as Neurology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 19 billing codes

Paid by Medicare

$62,848

Medicare's payments for the services billed

Medicare patients

468

Average age 72

Services billed

768

251 women, 217 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 51%
Depression 39%
Diabetes 37%
Ischemic heart disease 29%
COPD 23%
Chronic kidney disease 20%
Heart failure 18%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

2 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
UBRELVY
  • AbbVie, Inc. $8
$8 68 —
QULIPTA
  • AbbVie, Inc. $8
$8 34 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

160 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Neurology in Indiana

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2024

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record